DIVISLAB2023-04-012023-06-30 DIVISLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member DIVISLAB2023-06-30 DIVISLAB2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532488 DIVISLAB NOTLISTED Divi's Laboratories Limited Equity 2023-04-01 2024-03-31 2023-08-14 2023-08-05 INR Crores First quarter 11:30:00 12:40:00 2023-08-14 2023-08-14 Not applicable Single segment Manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients 2023-04-01 2023-06-30 Unaudited Consolidated 17780000000.00 810000000.00 18590000000.00 8290000000.00 0.00 -1410000000.00 2630000000.00 0.00 930000000.00 3230000000.00 13670000000.00 4920000000.00 0.00 4920000000.00 1250000000.00 110000000.00 1360000000.00 0.00 3560000000.00 0.00 0.00 0.00 0.00 3560000000.00 10000000.00 3570000000.00 3570000000.00 0.00 530000000.00 2 13.41 13.41 0.00 0.00 13.41 13.41 1.The above Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2023 (“Statement”) has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors of the Company at its meeting held on 14th August, 2023. The statutory auditors have carried out a limited review of the statement and issued an unmodified report thereon. 2.The consolidated financial results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”). 3.The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients; and the same constitutes a single reporting business segment as per Ind AS 108. 4.The Group does not have any discontinued operations and the Profit for the quarter represents the Profits from continuing operations only. 5.Details of Forex gain/(loss) are as given below. ( Rs. in Crores) Quarter Ended Year Ended 30.06.2023 31.03.2023 30.06.2022 31.03.2023 Forex gain/(loss) 3 (4) 56 130 Forex gain has been included in other income and loss has been included in other expenses. 6.*Figures for the quarter ended 31.03.2023 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year. ** Amount is below the rounding off norms adopted by the group. Other expenses 3230000000.00 Gain on Remeasurement of post-employment benefit obligations 10000000.00 10000000.00 10000000.00 Gain on exchange differences in translating the financial statements of a foreign operation 10000000.00 10000000.00 0.00